Search Results - "Browne, Barry J."

Human type I pancreatic elastase treatment of arteriovenous fistulas in patients with chronic kidney disease by Hye, Robert J., MD, Peden, Eric K., MD, O'Connor, Timothy P., MD, Browne, Barry J., MD, Dixon, Bradley S., MD, Schanzer, Andres S., MD, Jensik, Stephen C., MD, Dember, Laura M., MD, Jaff, Michael R., DO, Burke, Steven K., MD

“…Objective This study explored the safety and efficacy of recombinant type I pancreatic elastase (PRT-201) topically applied once to the external surface of an…”
Get full text

Arteriovenous fistula patency in the 3 years following vonapanitase and placebo treatment by Peden, Eric K., MD, O'Connor, Timothy P., MD, Browne, Barry J., MD, Dixon, Bradley S., MD, Schanzer, Andres S., MD, Jensik, Stephen C., MD, Sam, Albert D., MD, Burke, Steven K., MD

“…Abstract Objective This study explored the long-term outcomes of arteriovenous fistulas treated with vonapanitase (recombinant human elastase) at the time of…”
Get full text

The Venous Window Needle Guide, a hemodialysis cannulation device for salvage of uncannulatable arteriovenous fistulas by Jennings, William C., MD, Galt, Spencer W., MD, Shenoy, Surendra, MD, Wang, Shouwen, MD, PhD, Ladenheim, Eric D., MD, Glickman, Marc H., MD, Kathuria, Pranay, MD, Browne, Barry J., MD

“…Background Arteriovenous fistulas (AVFs) are recommended for hemodialysis access when possible. A noncannulatable but otherwise well functioning AVF leads to…”
Get full text

A randomized trial of vonapanitase (PATENCY-1) to promote radiocephalic fistula patency and use for hemodialysis by Bleyer, Anthony J., Scavo, Vincent A., Wilson, Samuel E., Browne, Barry J., Ferris, Brian L., Ozaki, C. Keith, Lee, Timmy, Peden, Eric K., Dixon, Bradley S., Mishler, Rick, O'Connor, Timothy P., Kidd, Kendrah, Burke, Steven K.

“…Arteriovenous fistulas created in patients with chronic kidney disease often lose patency and fail to become usable. This prospective trial evaluated the…”
Get full text

PATENCY-2 trial of vonapanitase to promote radiocephalic fistula use for hemodialysis and secondary patency by Peden, Eric K, Lucas, John F, Browne, Barry J, Settle, Stephen M, Scavo, Vincent A, Bleyer, Anthony J, Ozaki, Charles Keith, Teruya, Theodore H, Wilson, Samuel E, Mishler, Rick E, Ferris, Brian L, Hendon, Kendra S, Moist, Louise, Dixon, Bradley S, Wong, Marco D, Magill, Missy, Lindow, Francesca, Gustafson, Pamela, Burke, Steven K

“…Objective: Arteriovenous fistulas created for hemodialysis often fail to become usable and are frequently abandoned. This prospective trial evaluated the…”
Get full text

The impact of cytomegalovirus infection ≥1 year after primary renal transplantation by Browne, Barry J., Young, Jo-Anne, Dunn, Ty B., Matas, Arthur J.

“…Browne BJ, Young J‐A, Dunn TB, Matas AJ. The impact of cytomegalovirus infection ≥1 yr after primary renal transplantation.
Clin Transplant 2010: 24: 572–579…”
Get full text

Application of Human Type I Pancreatic Elastase (PRT-201) to the venous Anastomosis of Arteriovenous Grafts in Patients with Chronic Kidney Disease by Dwivedi, Amit J., Roy-Chaudhury, Prabir, Peden, Eric K., Browne, Barry J., Ladenheim, Eric D., Scavo, Vincent A., Gustafson, Pamela N., Wong, Marco D., Magill, Marianne, Lindow, Francesca, Blair, Andrew T., Jaff, Michael R., Franano, F. Nicholas, Burke, Steven K.

“…Purpose To explore the safety and efficacy of PRT-201 applied to the outflow vein of a newly created arteriovenous graft (AVG). Methods Randomized,…”
Get full text

A comparison of cryopreserved vein allografts and prosthetic grafts for hemodialysis access by Madden, Robert L, Lipkowitz, George S, Browne, Barry J, Kurbanov, Alexander

“…In hemodialysis patients with insufficient vasculature for creation of a native arteriovenous fistula (AVF), a polytetrafluoroethylene (PTFE) graft is commonly…”
Get more information

Experience with cryopreserved cadaveric femoral vein allografts used for hemodialysis access by Madden, Robert L, Lipkowitz, George S, Browne, Barry J, Kurbanov, Alexander

“…The purpose of this study was to review the patency and complications of cryopreserved vein allografts used for hemodialysis access, and to compare them to a…”
Get more information

The Role of Gender in Heart Transplantation by Prendergast, Thomas W, Furukawa, Satoshi, Beyer, A.James, Browne, Barry J, Eisen, Howard J, Jeevanandam, Valluvan

“…Background. The effect of donor and recipient gender on the outcome of heart transplantation (HT) remains uncertain. Methods. One hundred seventy-four patients…”
Get full text

Tacrolimus and ciclosporin microemulsion in renal transplantation by Emovon, Osemwegie E, Browne, Barry J

Get full text

Effects of limited work hours on surgical training by Browne, Barry J, Madden, Robert L, Kurbanov, Alexander, Lipkowitz, George S

Get full text

Delayed graft function may not adversely affect short-term renal allograft outcome by Browne, Barry J, Holt, Cynthia Op't, Emovon, Osemwegie E

“…: Introduction: Delayed graft function (DGF) is commonly believed to adversely impact both short‐ and long‐term renal allograft function. Because…”
Get full text

Management of Left Ventricular Assist Device Infection With Heart Transplantation by Prendergast, Thomas W., Todd, Barbara A., Beyer, A.James, Furukawa, Satoshi, Eisen, Howard J., Addonizio, V.Paul, Browne, Barry J., Jeevanandam, Valluvan

“…Background. Left ventricular assist devices (LVADs) are being used as bridges to heart transplantation (HT). Infection of the LVAD in this patient population…”
Get full text

Ranitidine-induced acute interstitial nephritis in a cadaveric renal allograft by Emovon, Osemwegie E., King, Judy A.C., Holt, Cindy Op't, Browne, Barry J.

“…Ranitidine frequently is used for preventing peptic ulceration after renal transplantation. This drug occasionally has been associated with acute interstitial…”
Get full text

Effect of cyclosporin pharmacokinetics on renal allograft outcome in African-Americans by Emovon, Osemwegie E, King, Judy AC, Holt, Cindy Op't, Singleton, Barbara, Howell, David, Browne, Barry J

“…:  African‐Americans (A‐As) experience inferior outcome after transplantation compared with other ethnic groups. Bioavailability of cyclosporin (CsA) has been…”
Get full text

Can a pharmacokinetic approach to immunosuppression eliminate ethnic disparities in renal allograft outcome? by Emovon, Osemwegie E, Op't Holt, Cindy, Browne, Barry J

“…: Although renal allograft outcome correlates more closely with area under the concentration time curve (AUC) for cyclosporin (CsA) compared with the 12‐h…”
Get full text

SP579VONAPANITASE (PRT-201, RECOMBINANT HUMAN TYPE I PANCREATIC ELASTASE) FOR IMPROVED ARTERIOVENOUS FISTULA OUTCOMES - LONG-TERM RESULTS by Burke, Steven K, Hye, Robert J, Peden, Eric K, O'Connor, Timothy P, Browne, Barry J, Dixon, Bradley S

Get full text

The Tricontinental Mycophenolate Mofetil Trial by Browne, B J

Get full text

Diurnal cyclosporine dosing optimizes exposure and reduces the risk of acute rejection after kidney transplantation by Browne, Barry J., Op'T Holt, Cynthia, Emovon, Osemwegie E.

“…Acute rejection (AR) following transplantation may be due to episodic subtherapeutic cyclosporine (CsA) levels related to diurnal variation of hepatic drug…”
Get full text